Iterum Therapeutics plc (ITRMF) Operating Expenses (2017 - 2025)

Iterum Therapeutics has reported Operating Expenses for 9 years, with the latest figure at $8.1 million in Q3 2025.

• On a quarterly basis, Operating Expenses rose 66.18% year-over-year to $8.1 million in Q3 2025; TTM through Sep 2025 was $21.0 million, a 20.51% decrease from a year earlier, with the FY2024 full-year figure at $18.7 million, down 60.61% from the prior year.
• Operating Expenses was $8.1 million for Q3 2025 at Iterum Therapeutics, up from $5.5 million in the prior quarter.
• The five-year high for Operating Expenses was $16.7 million in Q3 2023, with the low at $3.7 million in Q4 2024.
• Average Operating Expenses over 5 years is $7.3 million, with a median of $7.0 million recorded in 2021.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses surged 137.21% in 2023, then slumped 70.71% in 2024.
• Over 5 years, Operating Expenses stood at $6.8 million in 2021, then increased by 16.06% to $7.9 million in 2022, then surged by 44.22% to $11.4 million in 2023, then plunged by 67.89% to $3.7 million in 2024, then surged by 121.28% to $8.1 million in 2025.
• The last three Operating Expenses figures came in at $8.1 million (Q3 2025), $5.5 million (Q2 2025), and $3.7 million (Q1 2025), per Business Quant data.